thiotepa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, thiotepa derivatives 2638 52-24-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • thio-tepa
  • triethylenethiophosphortriamide
  • thiotepa
  • oncotepa
  • phosphorothioic acid triethylenetriamide
  • tespamin
  • tespamine
  • thiophosphamide
  • tepadina
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
  • Molecular weight: 189.22
  • Formula: C6H12N3PS
  • CLOGP: 0.52
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 9.03
  • ALOGS: -1.31
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.90 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.70 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
March 26, 2019 PMDA Sumitomo Dainippon Pharma
March 26, 2021 EMA RIEMSER Pharma GmbH
March 9, 1959 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mucosal inflammation 520.43 40.26 192 6418 46736 63435676
Human herpesvirus 6 infection 456.28 40.26 96 6514 2861 63479551
Acute graft versus host disease 439.17 40.26 100 6510 4328 63478084
Cytomegalovirus infection 340.15 40.26 114 6496 20838 63461574
Acute graft versus host disease in skin 263.14 40.26 63 6547 3389 63479023
Cytomegalovirus infection reactivation 254.50 40.26 63 6547 3900 63478512
Graft versus host disease in skin 242.16 40.26 57 6553 2848 63479564
Venoocclusive liver disease 237.23 40.26 62 6548 4773 63477639
Chronic graft versus host disease 233.27 40.26 56 6554 3046 63479366
Febrile neutropenia 228.52 40.26 146 6464 118303 63364109
Thrombotic microangiopathy 209.79 40.26 67 6543 10494 63471918
Graft versus host disease 207.68 40.26 60 6550 6703 63475709
Haematotoxicity 196.64 40.26 62 6548 9314 63473098
Encephalitis viral 192.71 40.26 43 6567 1689 63480723
Product use in unapproved indication 186.95 40.26 152 6458 178928 63303484
Adenovirus infection 176.16 40.26 46 6564 3525 63478887
Pre-engraftment immune reaction 175.98 40.26 29 6581 209 63482203
Cytomegalovirus viraemia 155.28 40.26 46 6564 5603 63476809
Graft versus host disease in gastrointestinal tract 146.70 40.26 39 6571 3202 63479210
Acute graft versus host disease in intestine 118.29 40.26 29 6581 1720 63480692
Thrombocytopenia 114.47 40.26 107 6503 151050 63331362
Bacterial sepsis 112.13 40.26 33 6577 3925 63478487
Neutropenia 112.11 40.26 113 6497 174892 63307520
Epstein-Barr virus infection 104.08 40.26 37 6573 8013 63474399
Venoocclusive disease 103.85 40.26 27 6583 2031 63480381
Acute lymphocytic leukaemia recurrent 101.24 40.26 27 6583 2242 63480170
Posterior reversible encephalopathy syndrome 98.44 40.26 44 6566 17301 63465111
BK virus infection 95.79 40.26 28 6582 3251 63479161
Transplant dysfunction 92.97 40.26 30 6580 4842 63477570
Viraemia 84.85 40.26 21 6589 1295 63481117
Viral haemorrhagic cystitis 77.39 40.26 18 6592 851 63481561
Transplant failure 76.14 40.26 20 6590 1565 63480847
Sepsis 75.26 40.26 86 6524 153037 63329375
Cystitis haemorrhagic 73.04 40.26 24 6586 4099 63478313
Neurotoxicity 68.35 40.26 34 6576 16956 63465456
Off label use 67.43 40.26 187 6423 674275 62808137
Gastroenteritis adenovirus 67.36 40.26 13 6597 246 63482166
Skin toxicity 66.02 40.26 23 6587 4691 63477721
Bacteraemia 64.76 40.26 33 6577 17315 63465097
Cytomegalovirus chorioretinitis 64.45 40.26 18 6592 1775 63480637
Chronic graft versus host disease in skin 63.91 40.26 15 6595 738 63481674
Fatigue 63.02 40.26 9 6601 888019 62594393
Neoplasm recurrence 61.80 40.26 19 6591 2619 63479793
Toxic erythema of chemotherapy 61.53 40.26 11 6599 134 63482278
Meningoencephalitis herpetic 61.47 40.26 16 6594 1208 63481204
Leukoencephalopathy 59.76 40.26 21 6589 4392 63478020
Multiple organ dysfunction syndrome 58.59 40.26 48 6562 56704 63425708
Hypogonadism female 57.28 40.26 8 6602 14 63482398
Cytomegalovirus urinary tract infection 54.96 40.26 9 6601 62 63482350
Post transplant lymphoproliferative disorder 53.40 40.26 20 6590 5011 63477401
Progressive multifocal leukoencephalopathy 52.30 40.26 26 6584 12945 63469467
Pulmonary arterial hypertension 51.37 40.26 31 6579 22546 63459866
Pyrexia 50.39 40.26 134 6476 470344 63012068
Dyspnoea 48.51 40.26 6 6604 661307 62821105
Engraftment syndrome 47.77 40.26 11 6599 497 63481915
Stem cell transplant 46.42 40.26 14 6596 1808 63480604
Leukaemia recurrent 46.12 40.26 13 6597 1325 63481087
Pain 45.02 40.26 11 6599 740617 62741795
Pulmonary vascular disorder 44.79 40.26 10 6600 393 63482019
Alveolar soft part sarcoma 44.63 40.26 8 6602 99 63482313
Osteosarcoma 42.54 40.26 8 6602 131 63482281
Arthralgia 42.17 40.26 5 6605 569705 62912707
Lower respiratory tract infection fungal 40.91 40.26 9 6601 330 63482082
JC virus infection 40.64 40.26 13 6597 2038 63480374

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mucosal inflammation 531.94 34.26 231 7870 38391 34910439
Cytomegalovirus infection 452.16 34.26 184 7917 25951 34922879
Acute graft versus host disease in skin 379.42 34.26 108 7993 5093 34943737
Acute graft versus host disease 342.77 34.26 105 7996 6398 34942432
Venoocclusive liver disease 305.66 34.26 101 8000 7865 34940965
Acute graft versus host disease in intestine 294.34 34.26 77 8024 2631 34946199
Human herpesvirus 6 infection 274.25 34.26 69 8032 2012 34946818
Adenovirus infection 269.01 34.26 83 8018 5174 34943656
Graft versus host disease in skin 261.60 34.26 76 8025 3849 34944981
Graft versus host disease in gastrointestinal tract 226.45 34.26 67 8034 3616 34945214
Haematotoxicity 188.31 34.26 71 8030 8123 34940707
Cytomegalovirus infection reactivation 169.00 34.26 58 8043 5060 34943770
Epstein-Barr virus infection 160.55 34.26 62 8039 7566 34941264
Febrile neutropenia 158.63 34.26 176 7925 136673 34812157
Chronic graft versus host disease 153.95 34.26 52 8049 4321 34944509
Engraftment syndrome 151.13 34.26 37 8064 960 34947870
Graft versus host disease 131.37 34.26 59 8042 10510 34938320
Venoocclusive disease 128.79 34.26 41 8060 2826 34946004
Product use in unapproved indication 127.29 34.26 146 7955 117353 34831477
Viral haemorrhagic cystitis 125.51 34.26 33 8068 1147 34947683
Thrombotic microangiopathy 109.20 34.26 52 8049 10578 34938252
Cytomegalovirus viraemia 103.69 34.26 45 8056 7385 34941445
BK virus infection 97.58 34.26 40 8061 5698 34943132
Graft versus host disease in liver 95.06 34.26 27 8074 1257 34947573
Cystitis haemorrhagic 94.57 34.26 39 8062 5640 34943190
Posterior reversible encephalopathy syndrome 94.09 34.26 46 8055 9908 34938922
Pulmonary vascular disorder 91.34 34.26 23 8078 671 34948159
Pulmonary arterial hypertension 87.47 34.26 42 8059 8697 34940133
Chronic graft versus host disease in skin 83.61 34.26 23 8078 951 34947879
Post transplant lymphoproliferative disorder 82.88 34.26 37 8064 6491 34942339
Off label use 80.99 34.26 246 7855 419278 34529552
Encephalitis viral 78.64 34.26 23 8078 1189 34947641
Pulmonary arteriopathy 70.83 34.26 13 8088 76 34948754
Parainfluenzae virus infection 70.37 34.26 26 8075 2804 34946026
Autoimmune lymphoproliferative syndrome 68.61 34.26 14 8087 152 34948678
Multiple organ dysfunction syndrome 67.77 34.26 86 8015 76480 34872350
Thrombocytopenia 64.09 34.26 123 7978 156124 34792706
Osteosarcoma 60.68 34.26 14 8087 279 34948551
Acute graft versus host disease in liver 60.57 34.26 20 8081 1546 34947284
Fatigue 59.28 34.26 8 8093 370645 34578185
Juvenile melanoma benign 59.00 34.26 11 8090 71 34948759
Pre-engraftment immune reaction 56.93 34.26 11 8090 88 34948742
Dyspnoea 53.89 34.26 11 8090 376771 34572059
Epstein-Barr viraemia 51.73 34.26 17 8084 1295 34947535
Cytomegalovirus chorioretinitis 50.92 34.26 22 8079 3567 34945263
Bacterial sepsis 48.82 34.26 24 8077 5226 34943604
Pneumonia cytomegaloviral 47.56 34.26 20 8081 3034 34945796
Idiopathic pneumonia syndrome 45.93 34.26 11 8090 259 34948571
Myelitis transverse 45.87 34.26 15 8086 1125 34947705
Sepsis 45.17 34.26 111 7990 166450 34782380
Bronchiolitis obliterans syndrome 43.50 34.26 10 8091 196 34948634
Autoimmune haemolytic anaemia 43.14 34.26 21 8080 4475 34944355
NPM1 gene mutation 42.61 34.26 9 8092 117 34948713
Neutropenia 40.94 34.26 103 7998 156675 34792155
Death 40.48 34.26 21 8080 398028 34550802
CNS ventriculitis 40.17 34.26 10 8091 278 34948552
Chronic graft versus host disease in liver 40.14 34.26 11 8090 448 34948382
Aplasia 39.77 34.26 20 8081 4568 34944262
Gastrointestinal toxicity 39.66 34.26 17 8084 2702 34946128
Respiratory syncytial virus infection 39.28 34.26 20 8081 4689 34944141
Clostridium difficile colitis 39.05 34.26 31 8070 15699 34933131
Retinopathy haemorrhagic 38.27 34.26 7 8094 40 34948790
Bone marrow failure 37.85 34.26 40 8061 29213 34919617
Asthenia 37.51 34.26 6 8095 245245 34703585
Multisystem inflammatory syndrome in children 37.31 34.26 6 8095 13 34948817
Encephalitis cytomegalovirus 36.91 34.26 11 8090 607 34948223
Chimerism 36.73 34.26 9 8092 234 34948596
Hyperfibrinogenaemia 36.12 34.26 7 8094 57 34948773
Chronic graft versus host disease in intestine 36.02 34.26 9 8092 254 34948576
Leukoencephalopathy 35.44 34.26 18 8083 4197 34944633
Bone sarcoma 34.92 34.26 7 8094 69 34948761

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mucosal inflammation 856.60 32.20 365 13869 75215 79654939
Cytomegalovirus infection 849.98 32.20 310 13924 42334 79687820
Acute graft versus host disease in skin 730.42 32.20 186 14048 7472 79722682
Human herpesvirus 6 infection 681.22 32.20 164 14070 5206 79724948
Acute graft versus host disease 632.00 32.20 176 14058 9991 79720163
Adenovirus infection 523.90 32.20 146 14088 8301 79721853
Venoocclusive liver disease 523.21 32.20 157 14077 11614 79718540
Graft versus host disease in skin 470.08 32.20 125 14109 5948 79724206
Acute graft versus host disease in intestine 449.17 32.20 111 14123 3930 79726224
Cytomegalovirus infection reactivation 412.24 32.20 122 14112 8594 79721560
Haematotoxicity 381.40 32.20 132 14102 15387 79714767
Febrile neutropenia 379.70 32.20 320 13914 230679 79499475
Graft versus host disease 339.28 32.20 120 14114 14906 79715248
Graft versus host disease in gastrointestinal tract 331.51 32.20 96 14138 6260 79723894
Product use in unapproved indication 324.01 32.20 303 13931 250056 79480098
Epstein-Barr virus infection 294.82 32.20 107 14127 14309 79715845
Chronic graft versus host disease 286.39 32.20 87 14147 6694 79723460
Thrombotic microangiopathy 277.02 32.20 112 14122 20057 79710097
Encephalitis viral 262.33 32.20 66 14168 2513 79727641
Venoocclusive disease 256.02 32.20 73 14161 4500 79725654
Cytomegalovirus viraemia 250.41 32.20 92 14142 12729 79717425
Pre-engraftment immune reaction 219.64 32.20 40 14194 301 79729853
Viral haemorrhagic cystitis 210.89 32.20 53 14181 2008 79728146
BK virus infection 205.12 32.20 72 14162 8732 79721422
Engraftment syndrome 183.56 32.20 44 14190 1365 79728789
Bacterial sepsis 164.40 32.20 60 14174 8138 79722016
Cystitis haemorrhagic 161.45 32.20 61 14173 9111 79721043
Posterior reversible encephalopathy syndrome 146.14 32.20 78 14156 26203 79703951
Chronic graft versus host disease in skin 139.04 32.20 36 14198 1538 79728616
Pulmonary vascular disorder 137.46 32.20 33 14201 1030 79729124
Off label use 133.12 32.20 408 13826 906807 78823347
Post transplant lymphoproliferative disorder 131.47 32.20 56 14178 11408 79718746
Pulmonary arterial hypertension 124.36 32.20 72 14162 28294 79701860
Fatigue 123.27 32.20 12 14222 929715 78800439
Thrombocytopenia 122.07 32.20 190 14044 265069 79465085
Multiple organ dysfunction syndrome 120.64 32.20 127 14107 120119 79610035
Autoimmune haemolytic anaemia 120.06 32.20 48 14186 8332 79721822
Sepsis 114.36 32.20 186 14048 269242 79460912
Neutropenia 104.08 32.20 185 14049 287525 79442629
Dyspnoea 103.82 32.20 15 14219 857010 78873144
Acute lymphocytic leukaemia recurrent 100.03 32.20 36 14198 4688 79725466
Osteosarcoma 99.09 32.20 21 14213 367 79729787
Acute graft versus host disease in liver 95.44 32.20 28 14206 1907 79728247
Transplant dysfunction 95.32 32.20 39 14195 7182 79722972
Pulmonary arteriopathy 91.13 32.20 16 14218 95 79730059
Cytomegalovirus chorioretinitis 84.07 32.20 33 14201 5457 79724697
Epstein-Barr viraemia 83.37 32.20 26 14208 2179 79727975
Gastroenteritis adenovirus 82.49 32.20 18 14216 363 79729791
Arthralgia 82.32 32.20 5 14229 571798 79158356
Leukoencephalopathy 81.96 32.20 36 14198 7893 79722261
Viraemia 80.59 32.20 27 14207 2842 79727312
Transplant failure 78.54 32.20 30 14204 4611 79725543
Toxic erythema of chemotherapy 77.85 32.20 16 14218 239 79729915
Skin toxicity 77.15 32.20 35 14199 8279 79721875
Graft versus host disease in liver 76.16 32.20 23 14211 1731 79728423
Respiratory syncytial virus infection 76.09 32.20 36 14198 9366 79720788
Dizziness 71.73 32.20 6 14228 526435 79203719
Pain 71.14 32.20 19 14215 703783 79026371
Autoimmune lymphoproliferative syndrome 70.44 32.20 14 14220 175 79729979
Parainfluenzae virus infection 69.28 32.20 29 14205 5653 79724501
Pyrexia 68.32 32.20 270 13964 678439 79051715
Neoplasm recurrence 66.89 32.20 26 14208 4188 79725966
Gastrointestinal toxicity 65.47 32.20 31 14203 8078 79722076
Bacteraemia 65.29 32.20 51 14183 32773 79697381
Pneumonia cytomegaloviral 62.74 32.20 26 14208 4943 79725211
Neurotoxicity 61.40 32.20 49 14185 32469 79697685
Focal nodular hyperplasia 60.85 32.20 16 14218 726 79729428
Metaplasia 60.22 32.20 15 14219 547 79729607
Stem cell transplant 59.31 32.20 23 14211 3681 79726473
Leukaemia recurrent 58.21 32.20 21 14213 2753 79727401
Myelitis transverse 57.39 32.20 19 14215 1928 79728226
Bone marrow failure 56.65 32.20 57 14177 51050 79679104
Pruritus 55.12 32.20 4 14230 394644 79335510
Idiopathic pneumonia syndrome 54.43 32.20 14 14220 582 79729572
Meningoencephalitis herpetic 53.03 32.20 18 14216 1971 79728183
Hypogonadism female 52.96 32.20 8 14226 14 79730140
Aplasia 51.46 32.20 26 14208 7794 79722360
Hepatotoxicity 51.00 32.20 54 14180 51298 79678856
Chronic graft versus host disease in intestine 50.66 32.20 12 14222 353 79729801
NPM1 gene mutation 49.95 32.20 10 14224 130 79730024
Clostridium difficile colitis 49.24 32.20 43 14191 32240 79697914
Malaise 47.98 32.20 14 14220 489855 79240299
Cytomegalovirus urinary tract infection 47.49 32.20 9 14225 86 79730068
Bone sarcoma 46.94 32.20 9 14225 92 79730062
Pericardial effusion 46.59 32.20 49 14185 46188 79683966
Multisystem inflammatory syndrome in children 46.40 32.20 8 14226 42 79730112
Bronchiolitis obliterans syndrome 46.30 32.20 11 14223 328 79729826
Headache 46.21 32.20 30 14204 653742 79076412
Rhinovirus infection 45.30 32.20 24 14210 7929 79722225
Disseminated toxoplasmosis 44.83 32.20 10 14224 224 79729930
Mucosal toxicity 44.74 32.20 12 14222 588 79729566
Asthenia 44.29 32.20 18 14216 511671 79218483
Toxoplasmosis 44.08 32.20 17 14217 2680 79727474
Chronic graft versus host disease in liver 43.48 32.20 12 14222 655 79729499
Chimerism 42.49 32.20 10 14224 286 79729868
Nausea 42.47 32.20 66 14168 957130 78773024
Encephalitis cytomegalovirus 41.14 32.20 13 14221 1137 79729017
Aplastic anaemia 40.40 32.20 30 14204 17875 79712279
Pulmonary veno-occlusive disease 40.38 32.20 14 14220 1634 79728520
Condition aggravated 39.66 32.20 20 14214 501104 79229050
Second primary malignancy 39.18 32.20 27 14207 14323 79715831
Pain in extremity 38.38 32.20 9 14225 364529 79365625
Cardiotoxicity 38.14 32.20 25 14209 12214 79717940
Acute respiratory distress syndrome 37.95 32.20 43 14191 44024 79686130
Weight decreased 36.94 32.20 9 14225 355189 79374965
Retinopathy haemorrhagic 36.56 32.20 7 14227 71 79730083
Constipation 36.46 32.20 4 14230 283046 79447108
Herpes simplex 35.81 32.20 24 14210 12163 79717991
Pancytopenia 35.47 32.20 86 14148 165659 79564495
Myelopathy 35.23 32.20 17 14217 4616 79725538
Back pain 35.16 32.20 6 14228 304174 79425980
Premature menopause 35.12 32.20 10 14224 612 79729542
Bacille Calmette-Guerin scar reactivation 35.04 32.20 6 14228 30 79730124
Alveolar soft part sarcoma 34.82 32.20 7 14227 93 79730061
Parvovirus B19 infection 34.06 32.20 12 14222 1468 79728686
Hyperfibrinogenaemia 34.03 32.20 7 14227 105 79730049
Myelodysplastic syndrome 33.94 32.20 34 14200 30267 79699887
Acute myeloid leukaemia recurrent 33.80 32.20 15 14219 3368 79726786
Abdominal discomfort 33.71 32.20 3 14231 250724 79479430
Herpes simplex reactivation 33.00 32.20 9 14225 470 79729684
Disease recurrence 32.93 32.20 40 14194 44069 79686085

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01AC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Ethylene imines
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D019653 Myeloablative Agonists
MeSH PA D009676 Noxae

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Allogeneic bone marrow transplantation indication 58390007
Hodgkin's disease indication 118599009
Malignant lymphoma indication 118600007 DOID:0060058
Non-Hodgkin's lymphoma indication 118601006
Malignant tumor of ovary indication 363443007 DOID:2394
Malignant tumor of urinary bladder indication 399326009 DOID:11054
Carcinoma of female breast indication 447782002
Pleural Malignant Effusions indication
Peritoneal Malignant Effusions indication
Pericardial Malignant Effusions indication
Acute infectious disease contraindication 63171007
Blood coagulation disorder contraindication 64779008 DOID:1247
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG/VIAL TEPADINA ADIENNE SA N208264 Jan. 26, 2017 RX POWDER INTRACAVITARY, INTRAVENOUS, INTRAVESICAL Jan. 26, 2024 INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
15MG/VIAL TEPADINA ADIENNE SA N208264 Jan. 26, 2017 RX POWDER INTRACAVITARY, INTRAVENOUS, INTRAVESICAL Jan. 26, 2024 INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 2B6 Enzyme INHIBITOR Ki 5.32 IUPHAR

External reference:

IDSource
4017910 VUID
N0000146261 NUI
D00583 KEGG_DRUG
4017910 VANDF
C0039871 UMLSCUI
CHEBI:9570 CHEBI
CHEMBL671 ChEMBL_ID
D013852 MESH_DESCRIPTOR_UI
DB04572 DRUGBANK_ID
7622 IUPHAR_LIGAND_ID
881 INN_ID
905Z5W3GKH UNII
5453 PUBCHEM_CID
10473 RXNORM
184712 MMSL
2134 MMSL
5573 MMSL
d00390 MMSL
002637 NDDF
387508004 SNOMEDCT_US
88997008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 0143-9309 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRACAVITARY ANDA 22 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 0143-9309 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRACAVITARY ANDA 22 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 0143-9565 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRACAVITARY ANDA 22 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 25021-246 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS ANDA 23 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 43598-171 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVESICAL ANDA 27 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 43598-650 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS ANDA 20 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 54879-014 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRACAVITARY ANDA 23 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 54879-014 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRACAVITARY ANDA 23 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 65219-029 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
Thiotepa Human Prescription Drug Label 1 68083-446 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS ANDA 27 sections
Thiotepa Human Prescription Drug Label 1 68083-503 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
Thiotepa Human Prescription Drug Label 1 69539-123 INJECTION, POWDER, FOR SOLUTION 15 mg INTRAVENOUS ANDA 25 sections
Thiotepa Human Prescription Drug Label 1 69539-124 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
TEPADINA HUMAN PRESCRIPTION DRUG LABEL 1 70121-1630 INJECTION, POWDER, FOR SOLUTION 15 mg INTRACAVITARY NDA 18 sections
TEPADINA HUMAN PRESCRIPTION DRUG LABEL 1 70121-1630 INJECTION, POWDER, FOR SOLUTION 15 mg INTRACAVITARY NDA 18 sections
TEPADINA HUMAN PRESCRIPTION DRUG LABEL 1 70121-1630 INJECTION, POWDER, FOR SOLUTION 15 mg INTRACAVITARY NDA 18 sections
TEPADINA HUMAN PRESCRIPTION DRUG LABEL 1 70121-1631 INJECTION, POWDER, FOR SOLUTION 100 mg INTRACAVITARY NDA 18 sections
TEPADINA HUMAN PRESCRIPTION DRUG LABEL 1 70121-1631 INJECTION, POWDER, FOR SOLUTION 100 mg INTRACAVITARY NDA 18 sections
TEPADINA HUMAN PRESCRIPTION DRUG LABEL 1 70121-1631 INJECTION, POWDER, FOR SOLUTION 100 mg INTRACAVITARY NDA 18 sections
Thiotepa HUMAN PRESCRIPTION DRUG LABEL 1 70860-220 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS ANDA 23 sections
Thiotepa Human Prescription Drug Label 1 72205-045 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS ANDA 25 sections
Thiotepa Human Prescription Drug Label 1 72205-046 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 25 sections